Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maine drug disposal bill dies

This article was originally published in The Tan Sheet

Executive Summary

The Maine Senate indefinitely postpones legislation passed by the House that would have impelled manufacturers to contribute to an "Unused Pharmaceutical Disposal Program Fund." The Senate placed LD 821 in legislative files March 26, effectively killing it. The Consumer Healthcare Products Association opposed the bill and favors consumer education on safe drug disposal (1"The Tan Sheet" March 22, 2010, In Brief)

You may also be interested in...



CHPA opposes Maine bill

The Consumer Healthcare Products Association opposes a bill approved by Maine's House of Representatives that would require drug manufacturers to fund a system for disposing of unwanted Rx and OTC drugs. A CHPA spokeswoman said the trade group instead supports consumers using "more effective means of ensuring safe medicine disposal which not only protect the environment, but also prevent illegitimate access to drugs, decrease potential abuse and limit accidental poisonings." CHPA backs the SMARxT Disposal campaign, which educates consumers on proper disposal of unwanted medicines and which the American Pharmacists Association supports. The bill received a 91-51 vote March 17 and moves next to the Senate

International Harmonization: Not Just For Audits Anymore

The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.

Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel